Physician profile
David Scherr
NPI 1053404764
$1,586.42
in general payments reported to CMS, 2019-2025
19 companies · $62.75 in 2025
The $62.75 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $188 · 2021: $205 · 2022: $134 · 2023: $304 · 2024: $259 · 2025: $62.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $382.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $350.84 | 2019-2025 | Vaxelis, Gardasil 9, M-M-R II |
| Kaleo, INC. | $243.90 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $130.31 | 2019-2024 | Doc Band |
| Sanofi Pasteur INC. | $88.62 | 2019-2023 | |
| Glaxosmithkline, LLC. | $70.90 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $41.09 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $40.21 | 2024-2025 | Ycanth |
| Seqirus USA INC | $27.49 | 2023 | Flucelvax Quadrivalent |
| Novo Nordisk INC | $25.69 | 2019 | |
| Alk-Abello, INC | $23.99 | 2023 | Ragwitek, Grastek, Odactra |
| Phadia US INC. | $23.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.53 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $21.47 | 2024 | Flumist Quadrivalent |
| Arbor Pharmaceuticals, INC. | $20.97 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.60 | 2019 | |
| Shire North American Group INC | $18.72 | 2019 | |
| Adlon Therapeutics L.P. | $17.49 | 2019 | |
| Genentech USA, INC. | $15.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scherr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.